HURA
TuHURA Biosciences, Inc./NV
NASDAQ · Healthcare · Biotechnology · US
$2.10
+0.48%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.09
From 52W high−33.33%
Volume173954.00
Market cap$133.83M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$2.09
From 52W high
−33.33%
Volume
173954.00
Market cap
$133.83M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.5x
P/E (TTM)
—
RSI (14)
48.8
MomentumView details →
1D Return
+0.48%
YTD Return
+176.86%
SummaryUpdated Jun 1, 2026
TuHURA Biosciences, Inc. (NASDAQ:HURA) is a clinical-stage biotechnology company founded in 2013 and headquartered in Tampa, Florida. The company focuses on developing novel immuno-oncology therapies designed to overcome resistance mechanisms that limit the effectiveness of current cancer immunotherapies. TuHURA has progressed to phase 3 registration-stage trials, representing a significant milestone in bringing potentially life-saving cancer treatments to market.
Similar companies
Latest newsMore news →
The U.S. FDA granted TuHURA Biosciences IND clearance and a "Study May Proceed" notice for its TBS-2025 VISTA-inhibiting antibody in molecularly defined subsets of AML and other blood-related cancers.6d agoParabilis Medicines, Inc. appointed Craig Tendler, M.D., as a director, effective August 22, 2026, and granted him a stock option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share.27d ago